Evaluation of efficacy and safety of intraoperative tranexamic acid: prospective placebo-controlled comparative study

Mohamed A. Lotfy\textsuperscript{a} and Samar A. Salman\textsuperscript{b}

\textsuperscript{a}Department of Anesthesia, Pain & ICU, Faculty of Medicine, Tanta University, Tanta, Egypt; \textsuperscript{b}Department of Anesthesia, Pain & ICU, Faculty of Medicine, Cairo University, Giza, Egypt

\textbf{ABSTRACT}

\textbf{Objectives:} Evaluation of the effect and safety of intravenous and local application of tranexamic acid (TXA) on outcomes of transurethral resection of the prostate (TURP).

\textbf{Patients & Methods:} 138 patients were divided into three groups according to the mode of TXA delivery (Groups I and II) or placebo. Hemoglobin concentration (HBC) and hematocrit value (HTC) were determined before and immediately after surgery to calculate hemoglobin deficit and estimated intraoperative blood loss (IO-BL). All surgeries were performed under bupivacaine spinal anesthesia with the preoperative saline co-load infusion.

\textbf{Results:} Patients who received TXA were compared with those who received placebo. The IO-BL was significantly lower in patients received TXA than placebo. Hemoglobin deficit after surgery was significantly lower in patients received both IV and local delivery of TXA than patients of other groups. No adverse effects of TXA were reported.

\textbf{Conclusion:} The applied policy for antifibrinolysis during TURP was safe and effectively improved operative and immediate PO outcomes.

\section{1. Introduction}

Tranexamic acid, which is a synthetic analog of the amino acid lysine, competitively inhibits the formation of the fibrinolysis complex through binding to lysine binding sites on plasminogen [1] to prevent its activation to plasin with subsequent prevention of fibrinolysis and stabilisation of the fibrin-rich clot [2]. TXA was on the list of World Health Organization essential medicines that are used to treat severe bleeding events for nearly 60 years [3]. TXA is used to control both intraoperative (IO) and postoperative (PO) bleeding during various surgical procedures [4]. Moreover, TXA was found to indirectly reduce post-surgery infection rates [5] and to decrease hemorrhage-related mortality in trauma patients [4].

TXA is routinely given intravenously, however, oral administration and local delivery of TXA to bleeding sites were found to achieve an effective and prolonged anti-fibrinolytic effect during various orthopedic surgeries [6,7]. Moreover, local delivery was found to be as effective as an intravenous infusion [8].

Transurethral resection of the prostate (TURP) is still the “gold standard” surgical treatment for medication-refractory benign prostatic hyperplasia (BPH) [9], but the incidence of IO and PO complications accounts for about 15% with bleeding is the most frequent complication [10].

\subsection{1.1. Objectives}

This study targets to evaluate the effect and safety of the intravenous and local delivery of TXA during TURP.

\subsection{1.2. Design}

Prospective interventional multicenter placebo-controlled comparative study.

\subsection{1.3. Setting}

Departments of Anesthesia, Faculty of Medicine, Tanta and Cairo Universities, and multiple private urology centers at Cairo and Tanta.

\subsection{1.4. Ethical consideration}

The study protocol was approved by the Local Ethical Committee at Tanta Faculty of Medicine (Approval code: 35,461/4/22). For blindness purposes, the authors and surgeons were blinded during the preparation of the wash fluid.

\subsection{1.5. Sample size calculation}

According to the published results obtained by Abboud et al. [11] regarding the effect of using combined intravenous and topical tranexamic acid in

\[ \text{CONTACT} \] Mohamed A. Lotfy \textsuperscript{a} mohamed.a.lotfy1988@gmail.com \textsuperscript{a} Department of Anesthesia & ICU, Faculty of Medicine, Tanta University, Tanta, Egypt

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
reduction of perioperative and considering the null hypothesis was as the absence of difference between all groups with a delta of 0.07, moderate effect size of 0.25 among 3 groups, using estimated sample sizes for one way ANOVA F test, the required minimal sample size was 42 subjects per group for a total sample size of 126 subjects to achieve a study power of 80% with a error of 5%. For possible attrition, sample size was increased to 138. Sample size was calculated by the STATA software (Stata Corp, 2021, Version 17).

1.6. Patients & methods
All patients assigned to TURP for BPH were evaluated for exclusion and inclusion criteria.

1.7. Exclusion criteria
Patients with coagulopathy, renal, liver, or cardiac diseases, obesity of grade II with body mass index (BMI) >35 kg/m², allergy to the study drugs, maintenance on drug therapy that may interact with TXA, presence of other prostatic or urinary bladder pathologies, refusal to receive neuraxial anesthesia or to sign the written consent were excluded from the study.

1.8. Inclusion criteria
Patients presenting with manifestations of obstructive uropathy secondary to BPH and were free of exclusion criteria were enrolled in the study.

1.9. Preoperative evaluation
(1) Determination of demographic data including age, weight, and height to calculate the BMI according to the equation: BMI = weight (kg)/ height (m²).
(2) Clinical examination includes the estimation of baseline hemodynamic data, ECG, and evaluation of the vertebral column for any deformity or obstacle to insertion of the spinal needle.
(3) Laboratory investigations include the determination of hemoglobin concentration (HGC), hematocrit value (Hct value), complete blood count, serum urea and creatinine, clotting, and bleeding times.

1.10. Randomization and grouping
Randomization sequence was created using Excel 2007 (Microsoft, Redmond, WA, USA) with a 1:1 allocation using random block sizes of 2 and 4 by an independent doctor. In this way, sequence generation and type of randomization can be expressed at the same time. For blindness purposes, the generated sequences were transformed as cards carrying group labels (I, II, III) put in sealed envelopes and was given to patient to provide it to the anesthetist, not the author, who was responsible for the preparation of the study infusions and irrigation fluids.

1.11. Preparation of infusions and irrigation fluids
(1) Intravenous infusions: three saline (0.9% NaCl) bottles were prepared and labeled I which is plain saline and II and III which contain TXA (Kapron, 500 mg/ 5 ml amp, Amoun Pharmaceuticals, Egypt) infusion of 500 mg/500 ml saline to provide 1:1 (wt: vol). Dose of TXA infusion was adjusted according to guidelines of the PeriOperative Tranexamic acid in hip arthroplasty (PORTO) study investigators who used a preoperative IV bolus of TXA 1 g followed by a continuous infusion of either TXA 1 g or placebo over 8 h [12]. IV infusions were started preoperatively at the time of induction of anesthesia till end of surgery and then were stopped.
(2) Irrigation fluid: normal saline (0.9 NaCl) was used as irrigation fluid; for patients of groups I and II saline irrigation bottles were free of TXA, while for patients of group III saline was mixed with TXA to provide 1 mg TXA for each 6 ml saline to provide 1:6 (wt: vol).

1.12. Anesthetic procedure
On arrival at the pre-anesthetic room, an 18-gauze cannula was inserted under complete aseptic conditions to prepare IV access and all patients were co-loaded with normal saline at a rate of 6 ml/kg/hr. Standard monitors were applied for non-invasive monitoring of heart rate, blood pressure, electrocardiography, and oxygen saturation. Central venous line, which is invasive procedure was not applied because the irrigation fluid to be used was saline not glycine, so there was no chance for hypervolemia. In the operating room, patients were kept in a set position, and after sterilization of the back, a 22-gauze needle was inserted at the level of L3-4 or L4-5 intervertebral space via midline or paramedian approach and 3-ml of 0.5% bupivacaine were injected after ensuring free flow of cerebrospinal fluid. Then, patients were placed in a supine position with one pillow. Non-invasive monitoring of hemodynamic variables was performed every 5-min all through operative time. Hypotension was considered if the mean arterial measure dropped by >20% of baseline value and was managed by intravenous injection of phenylephrine as a 50 µg bolus dose that was repeated after 5 min if indicated. Bradycardia was managed with intravenous atropine injection in a dose of 0.6 mg if the heart rate was dropped to <60/min. Surgeries were performed with
a Storz 24 Fr resectoscope, by one team in each institute. After completion of resection, a 20 Fr 3-way urethral Foley catheter with compression catheter balloon was applied to minimize the blood loss in all cases and bladder irrigation was stopped, so calculation of the postoperative blood loss was neglected as it will not be related to the study drug. Continuous normal saline irrigation was started after release of compression balloon until the urine drained from the urethral catheter became clear in the absence of irrigation and then catheters were removed and patients were discharged upon spontaneous voiding.

1.13. Evaluation of efficacy of anti-fibrinolytic therapy

- Estimated intraoperative blood loss (IO-BL) was calculated using the Gross formula [13] where BL = BV [HCT (i) – HCT (f)], where BV (ml) is the calculated blood volume as body weight (kg) multiplied by 70 [14], HCT (i) and HCT (f) were the initial (preoperative) and final (postoperative) hematocrit values, respectively.
- Hemoglobin deficit was calculated as the difference between preoperative and immediate PO hemoglobin concentration (HBC).
- The frequency of blood transfusion and the number of transfused blood units were also determined, if required.

1.14. Study outcomes

(1) The efficacy of anti-fibrinolytic therapy used for patients of groups II and III in comparison to group I
(2) The efficacy of the use of combined IV and local delivery of anti-fibrinolytic therapy compared to IV therapy only.
(3) The frequency of PO complications

2. Statistical methods

Data are presented as mean, standard deviation, median, interquartile range, numbers and percentages. Student t-test was used to determine the statistical significance of the difference between the mean values of two study group. One-way analysis of variance (ANOVA) was used for the comparison between mean values of more than two groups and Post-hoc test was followed to determine the difference between mean values of multiple groups. Mann Whitney Test (U test) was used to assess the statistical significance of the difference in non-parametric variables between two study groups. Chi-Square test was used to examine the relationship between two qualitative variables. Statistical analysis was conducted using IBM® SPSS® Statistics (Version 25, 2017; IBM Corp, Armonk, NY, USA) for Windows statistical package. P value <0.05 was considered statistically significant.

3. Results

During the study duration, 167 patients were eligible for evaluation; 29 were excluded for not fulfilling the inclusion criteria and 138 patients were randomly allocated into the three groups (Figure 1). The enrolment demographic and clinical data showed non-significant differences between patients of the three groups as shown in Table 1.

The weight of the resected prostatic tissue and the used volume of irrigation fluid showed a non-significant inter-group difference. The median value of intravenous dose used through intraoperative infusion was non-significant between patients of groups II and III. Operative time, duration of PO catheterization and hospital stay were significantly shorter in patients of group III compared to patients of group I and II with non-significant differences between patients of groups I and II (Table 2).

Figure 1. Study flowchart.
Table 1. Patients' enrolment data.

| Variables         | Group I       | Group II      | Group III     | P1      | P2      | P3      |
|-------------------|---------------|---------------|---------------|---------|---------|---------|
| Age (years)       | 66.3 ± 4.15   | 66.5 ± 3.9    | 66.8 ± 5.3    | 0.976   | 0.855   | 0.944   |
| Weight (kg)       | 89 ± 5.2      | 88 ± 5.7      | 88.5 ± 5.5    | 0.656   | 0.899   | 0.809   |
| Height (cm)       | 171 ± 4.8     | 170.5 ± 3.4   | 169 ± 3.8     | 0.826   | 0.052   | 0.185   |
| BMI (kg/m²)       | 30.2 ± 2.14   | 30.3 ± 2.4    | 31 ± 2.1      | 0.977   | 0.207   | 0.295   |
| US-estimated PV(cc)| 65 ± 7.6     | 67 ± 5        | 67.5 ± 5.5    | 0.262   | 0.064   | 0.764   |

Data are presented as a mean and standard deviation; IV: TXA: Intravenous tranexamic; BMI: Body mass index; US: Ultrasound; PV: Prostatic volume; P1 value indicates the significance of the difference between groups I & II; P2 value indicates the significance of the difference between groups I & III; P3 value indicates the significance of the difference between groups II & III; P < 0.05 indicates a significant difference; P > 0.05 indicates a non-significant difference.

Table 2. Operative and immediate PO data.

| Variables                  | Group I       | Group II      | Group III     | P1      | P2      | P3      |
|----------------------------|---------------|---------------|---------------|---------|---------|---------|
| Weight of the resected prostatic tissue (gm.) | 17.7 ± 1.85   | 17.2 ± 1.6    | 17.5 ± 1.9    | 0.378   | 0.855   | 0.703   |
| Operative time (min)       | 49.2 ± 5.3    | 47.7 ± 5.7    | 46.4 ± 6      | 0.241   | 0.024   | 0.136   |
| Number of bottles used for IO irrigation* | 6 [5.5–6.5]  | 5.5 [5–6.5]  | 5.55 [5–6.1]  | 0.242   | 0.053   | 0.352   |
| Dose of TXA(mg/ kg BW)*    | IV infusion   | 0             | 7.5 [7.3–7.8] | 0       | 0       | 0.659   |
|                           | Irrigation fluid | 0             | 7.4 [7.3–7.9] | 0       | 0       | 0       |
|                           | Total dose     | 0             | 4.07 [36–47]  | 0       | 0       | 0       |
| Catheter duration (hrs.)   | 93.9 ± 32.2   | 91.7 ± 29.7   | 77.1 ± 21.3   | 0.927   | 0.013   | 0.037   |
| Hospital stay (days)       | 4.1 ± 1.4     | 4 ± 1.3       | 3 ± 0.9       | 0.662   | 0.004   | 0.002   |

Data are presented as mean and standard deviation, median and interquartile range [IQR]*; TXA: Tranexamic acid; BW: Bodyweight; P1 value indicates the significance of the difference between groups I & II; P2 value indicates the significance of the difference between groups I & III; P3 value indicates the significance of the difference between groups II & III; P < 0.05 indicates a significant difference; P > 0.05 indicates a non-significant difference.

Preoperative HTC-i and HBC-i showed non-significant differences between studied groups, but were significantly higher than PO values (HTC-f and HBC-f). However, the HTC-f value of patients of group I was significantly lower in comparison to that of patients of group II (p = 0.0084) and group III (p = 0.0009) with a non-significantly (p = 0.774) higher HTC-f value of patients of group III in comparison to patients of group II.

The estimated IO-BL loss was significantly lower in patients of group III compared to patients of groups I (p < 0.001) and II (p = 0.0044) with significantly (p < 0.001) lower IO-BL in patients of group II than patients of group I. On contrary, HBC-f of patients of group III was significantly (p = 0.0019) higher but was non-significantly (p = 0.203) higher compared to patients of groups I and II, respectively with non-significantly (p = 0.181) higher HBC-f value in patients of group II. However, HBC deficit was significantly (p < 0.001) lower in patients of group III compared to patients of other with significantly (p = 0.0006) lower HBC deficit in patients of group II than group I. Only one patient in group I required transfusion of one bag of blood to correct his PO hemoglobin concentration (Table 3).

4. Discussion

The preoperative use of TXA significantly minimized intraoperative (IO) bleeding compared to placebo; this finding goes in hand with the recently documented as regarding the advantageous use of TXA for control of IO bleeding, irrespective of the type of surgery [15,16] and could be attributed to its mechanism of action through blockage of plasminogen-lysin binding sites to prevent binding of fibrin with subsequent stabilization of fibrin clot and prevention of bleeding [17–19]. Moreover, preoperative injection of a loading dose with induction of anesthesia before inflection of tissue injury and continuation with intravenous infusion during surgery, which continued for less than 60 min, could be a piece of practical evidence for the efficacy of the applied policy of the combined use of antifibrinolytic drugs as prophylaxis and therapy during surgery for control of perioperative bleeding and supported the previous work used similar policy during orthopedic surgeries [20–22].

Application of the antifibrinolytic drug direct topically through the irrigation fluid significantly reduced the amount of blood in the returning fluid in patients who received intravenous and local antifibrinolytic drug compared to patients who received intravenous injection only. The obtained superior outcome was reflected as shorter operative and PO hospital stay times and spared the needs for transfusion without increasing the thromboembolic risks as previously documented [7,23–27].

Using a similar combination in a placebo controlled study, Gupta et al. [28] detected significant reduction of bleeding and need for transfusion, but reported non-significant differences in PO HBC and did not explain this discrepancy. On contrary, the present work reported a significantly lower HBC deficit with the used combination compared to IV TXA only or placebo. Moreover, Gupta et al. [28] used intravenous drug 500 mg as a shot dose and 500 mg/3-L bottles for a maximum topical dose of 1.5 g of TXA; 3 bottles for a total dose of 2 g/patient. However, the mean number of bottles they were used was 5 (±1.5), thus there were plain two bottles (6 liters) were used without any
Table 3. Hematological data at end of surgery in comparison to preoperative data of patients of the three study groups.

| Variables               | Group  | I     | II    | III   | P1    | P2    | P3    |
|------------------------|--------|-------|-------|-------|-------|-------|-------|
| Estimated IO-BL        | HTC-i (%) | 39.5 ± 1.95 | 39.4 ± 2.1 | 39.2 ± 2.4 | 0.979 | 0.833 | 0.922 |
|                       | HTC-f (%) | 36.1 ± 1.65 | 37.5 ± 2.2 | 37.8 ± 2.5 | 0.0084 | 0.0009 | 0.774 |
|                       | P4 value  | <0.001 | <0.001 | 0.006 |       |       |       |
|                       | EBL (ml)  | 548.5 ± 142 | 307.8 ± 95 | 233 ± 87.6 | <0.001 | <0.001 | 0.0044 |
| Calculated HB deficit  | HBC-i (g/dl) | 12.8 ± 0.9 | 12.9 ± 1 | 12.8 ± 0.9 | 0.816 | 0.987 | 0.892 |
|                       | HBC-f (g/dl) | 11.5 ± 0.8 | 11.8 ± 1 | 12.1 ± 0.9 | 0.181 | 0.0019 | 0.203 |
|                       | P4 value  | <0.001 | <0.001 | 0.0004 |       |       |       |
|                       | Deficit (%) | 10 | 0.58 | 5.44 | 0.0006 | <0.001 | <0.001 |

Data are presented as mean and standard deviation, median and interquartile range (IQR); HTC-i: preoperative hematocrit; HTC-f: Hemocrit value estimated at end of surgery; HBC-i: preoperative hemoglobin concentration; HBC-f: Hemoglobin concentration estimated at end of surgery; EBL: Estimated blood loss; HB: Hemoglobin; P1 value indicates the significance of the difference between groups I & II; P2 value indicates the significance of the difference between groups I & III; P3 value indicates the significance of the difference between groups II & III; P value indicates the significance of the difference between estimations at the end of surgery and preoperatively; P < 0.05 indicates a significant difference; P > 0.05 indicates a non-significant difference.

5. Conclusion

Combined intravenous injection and topical TXA safely and effectively reduces bleeding and time of urinary bladder drainage and hospitalization of patients undergoing urethrosopic prostatic resection.

Acknowledgments

The authors provide great thanks to staff members of the Urology Departments at the hospitals included in the study.

Disclosure statement

No potential conflict of interest was reported by the author(s).

References

[1] Tengborn L, Blomback M, Berntorp E. Tranexamic acid - an old drug still going strong and making a revival. Thromb Res. 2015;135(2):231-42.
[2] Lin H, Xu L, Yu S, et al. Xu Therapeutics targeting the fibrinolytic system. Exp Mol Med. 2020;52(3):367-79.
[3] Hohmann E. Editorial commentary: the current evidence in support of tranexamic acid in arthroscopic surgery is poor. Arthroscopy. 2022;Feb;38(2):519–522.
[4] Godec S, Gradisek M, Mirkovic T, et al. Venticulolumbar perfusion and inhalational anaesthesia with sevoflurane in an accidental intrathecal injection of tranexamic acid: unsupported treatment options. Reg Anesth Pain Med. 2022 Jan;47(1):65–68.
[5] Benjumea A, Diaz-Navarro M, Hafan R, et al. Effect of tranexamic acid against staphylococcus spp. and cuti-bacterium acnes associated with peri-implant infection: results from an in vitro study. Microbiol Spectr. 2022 Feb 16;10(1):e0161221.
[6] Ker K, Beecher D, Roberts I. Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database Syst Rev. 2013 Jul 23;7. CD010562.
[7] Jansen JA, Lameijer JRC, Snoeker BAM. Combined intravenous, topical and oral tranexamic acid administration in total knee replacement: evaluation of safety in patients with previous thromboembolism and effect on hemoglobin level and transfusion rate. Knee. 2017 Oct;24(5):1206–1212.
[8] Montroy J, Hutton B, Moodley P, et al. The efficacy and safety of topical tranexamic acid: a systematic review
and meta-analysis. Transfus Med Rev. 2018 Feb 19; S0887-7963(17):30151–30157.
[9] Shvero A, Calio B, Humphreys M, et al. The new gold standard for surgical treatment of benign prostatic hyperplasia. Can J Urol. 2021 Aug;28(2):6–10.
[10] Zhang W, Zhang W, Guo Q, et al. The design and rationale of a multicentre randomised controlled trial comparing transperineal percutaneous laser ablation with transurethral resection of the prostate for treating benign prostatic hyperplasia. Front Surg. 2021 Oct 18:8:755957.
[11] Abboud NM, Kapila AK, Abboud S, et al. The combined effect of intravenous and topical tranexamic acid in liposuction: a randomized double-blinded controlled trial. Aesthet Surg J Open Forum. 2021 Jan;12(3):1: oja002. doi
[12] Lanoiselée J, Zufferey PJ, Ollier E, et al. PeriOperative Tranexamic Acid in Hip arthroPlasty (PORTO) study investigators: is tranexamic acid exposure related to blood loss in Hip arthroplasty? A pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol. 2018 Feb;84(2):310–319.
[13] Gross JB. Estimating allowable blood loss: corrected for dilution. Anesthesiology. 1983;58(3):277–280.
[14] Mc Swiney MM, O’Farrell D, Joshi GP, Mc carroll SM. Blood transfusion in total hip arthroplasty: guidelines to eliminate overtransfusion. Can J Anaesth. 1993;40(3):222–226.
[15] Koh A, Adimah A, Gomez D, et al. Safety and efficacy of tranexamic acid in minimizing perioperative bleeding in extrahepatic abdominal surgery: meta-analysis. BJS Open. 2021 Mar S;5(2):zrab004.
[16] Ikwuezumna L, Margalit A, Sponseller P. Tranexamic acid use is associated with reduced intraoperative blood loss during spine surgery for Marfan syndrome. Spine Deform. 2022 Mar;10(2):419–423.
[17] Van Aelbroeck C, Englbberger L, Faraoni D. Review of the fibrinolytic system: comparison of different antifibrinolytics used during cardiopulmonary bypass. Recent Pat Cardiovasc Drug Discov. 2012 Dec;7(3):175–179.
[18] Medcalf RL. What drives “fibrinolysis”? Hamostaseologie. 2015;35(4):303–310.
[19] Draxler D, Medcalf R. Fibrinolysis and tranexamic acid: mechanistic principles. ANZ J Surg. 2020 Apr;90(4):410–411.
[20] Pradhan R, Pandey B. Does tranexamic acid reduce perioperative bleeding in short segment pedicle screw fixation in thoracolumbar spine fractures? JNMA J Nepal Med Assoc. 2015 Jul-Sep;53(199):169–173.
[21] Wang H, Wang L, Luo Z, et al. Intravenous and subsequent long-term oral tranexamic acid in enhanced-recovery primary total knee arthroplasty without the application of a tourniquet: a randomized placebo-controlled trial. BMC Musculoskelet Disord. 2019 Oct 25;20(1):478.
[22] Mei A, Qiu L. The efficacy of tranexamic acid for orthognathic surgery: a meta-analysis of randomized controlled trials. Int J Oral Maxillofac Surg. 2019 Oct;48(10):1323–1328.
[23] Kim K, Bae J, Kim J, et al. Tranexamic acid in a periaortic multimodal cocktail injection for blood management in total knee arthroplasty: a prospective randomized study. BMC Musculoskelet Disord. 2021 Aug 10;22(1):675.
[24] Juraj M, Jaroslav V, Gažová A, et al. Evaluation of efficacy and safety of systemic and topical intra-articular administration of tranexamic acid in primary unilateral total Hip arthroplasty. Medicine (Baltimore). 2021 Jul 2;100(26):e26565.
[25] Ausen K, Fossmark R, Spigset O, et al. Safety and efficacy of local tranexamic acid for the prevention of surgical bleeding in soft-tissue surgery: a review of the literature and recommendations for plastic surgery. Plast Reconstr Surg. 2022 Mar 1;149(3):774–787.
[26] Longo M, Cavalheiro B, Filho G. Systematic review and meta-analyses of tranexamic acid use for bleeding reduction in prostate surgery. J Clin Anesth. 2018 Aug;48:32–38.
[27] Meng Q, Pan N, Xiong J, et al. Tranexamic acid is beneficial for reducing perioperative blood loss in transurethral resection of the prostate. Exp Ther Med. 2019 Jan;17(1):943–947.
[28] Gupta A, Priyadarshi S, Vyas N, et al. Efficacy of tranexamic acid in decreasing primary hemorrhage in transurethral resection of the prostate: a novel combination of intravenous and topical approach. Urol Ann. 2021 Jul-Sep;13(3):238–242.
[29] Tawfick A, Mousa W, El-Zhary AF, et al. Can tranexamic acid in irrigation fluid reduce blood loss during monopolar transurethral resection of the prostate? A randomized controlled trial. Arab J Urol. 2022 Jan 23;20(2):94–99.
[30] Chen L, Zhao C, Luo Y, et al. Different doses of intravenous tranexamic acid in revision total knee arthroplasty: a retrospective study. J Knee Surg. 2021 Dec 24. DOI:10.1055/s-0041-1740585.
[31] Poeran J, Chan J, Zubizarreta N, et al. Safety of tranexamic acid in Hip and knee arthroplasty in high-risk patients. Anesthesiology. 2021 Jul;135(1):57–68.
[32] Wang E, Yuan X, Wang Y, et al. Tranexamic acid administered during off-pump coronary artery bypass graft surgeries achieves good safety effects and hemostasis. Front Cardiovasc Med. 2022 Feb 4;9:77570.
[33] Ortner G, Nagle U, Herrmann TRW. Tokas T: irrigation fluid absorption during transurethral bipolar and laser prostate surgery: a systematic review. World J Urol. 2022 Mar;40(3):697–708.
[34] Okuma N, Hino H, Kuroki M, et al. Symptomatic absorption of normal saline during transurethral resection of the prostate: a case report. JA Clin Rep. 2022 Jun 21;8(1):43.